Moreover, targeting of TAMs with a selective CSF-1R inhibitor (AZD7507) in a genetic PDAC mouse model dramatically reduced tumor growth, enhanced T cell immune response and increased mouse survival in a difficult-to-treat model (Candido et al., 2018). This evidence concerns the gene CSF1R and neoplasm.